InvestorsHub Logo
Followers 87
Posts 1159
Boards Moderated 0
Alias Born 09/10/2017

Re: flipper44 post# 480424

Wednesday, 06/01/2022 1:44:16 PM

Wednesday, June 01, 2022 1:44:16 PM

Post# of 700436
The tumor response rate is the most commonly used surrogate endpoint in early cancer trials since it allows an early determination of anti-tumor activity, which may correlate to extended survival. Some immune checkpoint inhibitors were even approved on the basis of tumor response end points in nonrandomized trials.

In an interview a couple years ago with Al Musella, Stephen Brem said, “They’re looking at radiological markers. We do need a better biomarker that would really make all these trials to be more meaningful and be able to stop an effective trial, be able to accelerate effective when we see effective.” ( I transcribed the relevant part of the interview here)

So yes, if Northwest Bio can identify biomarkers that show that tumor response can predict longer survival, and is a meaningful endpoint, that would be huge, not only for this trial, but all future trials.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News